Position in FTRE
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,395,875
New position
Shares Held
137,694
first reported quarter
Ownership
0.145%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#74
of 334 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026SEGALL BRYANT & HAMILL, LLC holds $322,746,195 across 29 Biotechnology names. FTRE ranks #22 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTGX |
Protagonist Therapeutics, Inc
|
214,724 | $26,320,867 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
317,924 | $24,883,911 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
65,211 | $24,236,972 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
271,735 | $22,165,423 | |
| 5 | TECH |
BIO-TECHNE Corp
|
312,035 | $22,045,272 | |
| 6 | CYTK |
Cytokinetics Inc
|
257,063 | $21,899,196 | |
| 7 | MIRM |
Mirum Pharmaceuticals, Inc.
|
178,980 | $20,953,188 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
37,072 | $18,414,774 |
All Filings in FTRE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,395,875 | 137,694 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||